Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
309 results about "Reverse-transcriptase inhibitor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Reverse-transcriptase inhibitors (RTIs) are a class of antiretroviral drugs used to treat HIV infection or AIDS, and in some cases hepatitis B. RTIs inhibit activity of reverse transcriptase, a viral DNA polymerase that is required for replication of HIV and other retroviruses.
4-oxoquinoline compound and use thereof as pharmaceutical agent
An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I]wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.
Owner:JAPAN TOBACCO INC
Topical Antiviral Formulations
InactiveUS20080035155A1Reduce riskPrevent and reduce riskBiocideOrganic active ingredientsTopical antiviralReverse transcriptase
The present invention relates to formulations of nucleotide reverse transcriptase inhibitors (N(t)RTIs), preferably [2-(6-Amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenofovir, PMPA), or a physiologically functional derivative thereof, suitable for topical application and their use in the prevention of HIV infections.
Owner:EASTERN VIRGINIA MEDICAL SCHOOL +1
Compressed tablet formulation
This invention relates to a 50% drug loaded compressed tablet formulation for efavirenz. Efavirenz is a non-nucleoside reverse trancriptase inhibitor being studied clinically for use in the treatment of HIV infections and AIDS.
Owner:MERCK SHARP & DOHME CORP
Compressed tablet formulation
InactiveUS7060294B2Organic active ingredientsCapsule deliveryNucleoside Reverse Transcriptase InhibitorClinical study
This invention relates to a 50% drug loaded compressed tablet formulation for efavirenz. Efavirenz is a non-nucleoside reverse trancriptase inhibitor being studied clinically for use in the treatment of HIV infections and AIDS.
Owner:MERCK SHARP & DOHME CORP
HIV reverse transcriptase inhibitors
Compounds having the structure:
are HIV reverse transcriptase inhibitors, wherein A, X, Y, Z, R1 and R2 are defined herein. The compounds and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
Owner:MERCK SHARP & DOHME CORP
N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]-p-amino benozioc acids as HIV reverse transcriptase inhibitors
A series of S-triazolyl α-mercaptoacetanilides having N-(α-mercaptoacetyl) p amino benzoic acid derivatives.are provided, where Q is CO2H, or a salt or ester thereof, or a C(O)N-linked amino acid. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.![N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]-<i>p</i>-amino benozioc acids as HIV reverse transcriptase inhibitors](https://images-eureka.patsnap.com/patent_img/0efc470b-2453-496c-a38c-02b8a1dc5ec7/US07435752-20081014-C00001.png "N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]-<i>p</i>-amino benozioc acids as HIV reverse transcriptase inhibitors")
![N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]-<i>p</i>-amino benozioc acids as HIV reverse transcriptase inhibitors](https://images-eureka.patsnap.com/patent_img/0efc470b-2453-496c-a38c-02b8a1dc5ec7/US07435752-20081014-C00002.png "N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]-<i>p</i>-amino benozioc acids as HIV reverse transcriptase inhibitors")
![N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]-<i>p</i>-amino benozioc acids as HIV reverse transcriptase inhibitors](https://images-eureka.patsnap.com/patent_img/0efc470b-2453-496c-a38c-02b8a1dc5ec7/US07435752-20081014-C00003.png "N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]-<i>p</i>-amino benozioc acids as HIV reverse transcriptase inhibitors")
Owner:ARDEA BIOSCIENCES INC
4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
ActiveUS20050239819A1Promote absorptionIncreased riskBiocideOrganic chemistrySide effectReverse transcriptase
An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I]
wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.
Owner:JAPAN TOBACCO INC
Non-nucleoside reverse transcriptase inhibitors
ActiveUS20050239881A1Inhibit HIV reverse transcriptaseReduce sensitivityBiocideOrganic chemistryNucleoside Reverse Transcriptase InhibitorMedicine
The present invention provides compounds for treating or preventing an HIV infection, or treating AIDS or ARC comprising administering a compound according to formula I where Ar, R1-R5, R7a, R7b, R7c, R8-R10, X1, X2 m, n, o and p are as defined herein.
Owner:ROCHE PALO ALTO LLC
Non nucleoside reverse transcriptase inhibitors
InactiveUS20060128692A1Compound screeningBiocideNucleoside Reverse Transcriptase InhibitorReverse transcriptase activity
Phosphorus-substituted imidazole compounds with anti-HIV properties having use as therapeutics and for other industrial purposes are disclosed. The compositions inhibit reverse transcriptase activity and are useful therapeutically for the inhibition of such enzymes, as well as in assays for the detection of such enzymes.
Owner:GILEAD SCI INC
Nucleic acid amplification system and freeze-drying protective agent thereof
InactiveCN105463125AHigh sensitivityAchieving Freeze DryingMicrobiological testing/measurementConcentration ratioReverse transcriptase
The invention discloses a nucleic acid amplification system and a freeze-drying protective agent thereof. The nucleic acid amplification system comprises a buffer solution, an enzyme mixing solution, a nucleic acid amplification reaction solution and the low-temperature freeze-drying protective agent. The buffer solution further comprises one or more of dNTP, Mgcl2, Thris-Hcl and KCl. The enzyme mixing solution further comprises one or more of RNA reverse transcriptase, RAN inhibitor and DNA polymerase. A preparation method for the freeze-drying protective agent applied to the nucleic acid amplification system comprises the following step that the components are mixed to be uniform according to the adopted concentration ratio to obtain the freeze-drying protective agent. An RNA / DNA fluorescent quantitation nucleic acid diagnostic reagent system can be detected in a freeze-drying mode, freeze drying can be achieved, the detection purpose can be achieved only through one-step hydration, and the purposes of normal temperature transportation and storage which cannot be achieved by a nucleic acid diagnostic reagent at the present stage can be achieved.
Owner:江苏正大天创生物工程有限公司
Treatment for lipodystrophy
ActiveUS20130338209A1Prevention and treatment and alleviation of symptomPrevention alleviationBiocideOrganic chemistryLipoatrophyReverse transcriptase
The present invention provides a therapeutic compound of formula (I) and their pharmaceutically acceptable salts for the prevention and treatment of lipodystrophy caused because of HIV infection or combination therapy of HIV-1 protease inhibitors (Pis) and/or reverse transcriptase inhibitors (nRTIs) by neutralizing lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.
Owner:CADILA HEALTHCARE LTD
Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
ActiveUS20060052361A1Effective anti-HIV agentStrong inhibitory activityBiocideOrganic chemistryAnti-HIV AgentSide effect
The present invention relates to a nitrogen-containing fused ring compound represented by the following formula [I]wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, and an anti-HIV agent containing such compound. The compound of the present invention has an HIV integrase inhibitory activity, and is useful as an agent for the prophylaxis or treatment of AIDS, or as an anti-HIV agent. In addition, by the combined use with other anti-HIV agents such as a protease inhibitor, a reverse transcriptase inhibitor and the like, it can be a more effective anti-HIV agent. Becuae it shows integrase-specific high inhibitory activity, the compound can be a pharmaceutical agent safe on human body, which causes only a fewer side effects.
Owner:JAPAN TOBACCO INC
Non-nucleoside reverse transcriptase inhibitors
InactiveUS20080249131A1BiocideOrganic chemistryNucleoside Reverse Transcriptase InhibitorNon nucleoside inhibitor
Various carbonyl amides are employed in vitro and in vivo as non-nucleoside inhibitors of a reverse transcriptase, and particularly of HIV reverse transcriptase. Therefore, contemplated compounds may be employed in the treatment of HIV infected patients. Further contemplated aspects include pharmaceutical compositions comprising therapeutically effective amounts of contemplated compounds.
Owner:ARDEA BIOSCIENCES INC
Combination therapy
ActiveUS20050288326A1Low effective doseLow cytotoxicityBiocideAntiviralsSide effectReverse transcriptase
The present invention relates to a combination therapy for treating an HIV infection or inhibiting integrase comprising (S)-6-(3-Chloro-2-fluorobenzyl)-1-(1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (“Compound A”) or a pharmaceutically acceptable solvate or salt thereof in combination with at least one other anti-HIV agent. In some embodiments of the present invention, the other anti-HIV agents are chosen from reverse transcriptase inhibitors and protease inhibitors. In certain embodiments of the present invention, the other anti-HIV agents are chosen from AZT, 3TC, PMPA, efavirenz, indinavir, nelfinavir, a combination of AZT/3TC, and a combination of PMPA/3TC. Since Compound A has a high inhibitory activity specific for integrases, when used in combinations with other anti-HIV agents it can provide a combination therapy with fewer side effects for humans.
Owner:JAPAN TOBACCO INC
N[S(4-aryl-triazol-3-yl)alpha-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors
A series of S-triazolyl α-mercaptoacetanilides having N-(α-mercaptoacetyl) p amino benzoic acid derivatives.
are provided, where Q is CO2H, or a salt or ester thereof, or a C(O)N-linked amino acid. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.
![N[S(4-aryl-triazol-3-yl)alpha-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors](https://images-eureka.patsnap.com/patent_img/0ddecf1c-7904-4c8e-90a6-e64e68e68c14/US20060270725A1-20061130-C00001.png "N[S(4-aryl-triazol-3-yl)alpha-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors")
![N[S(4-aryl-triazol-3-yl)alpha-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors](https://images-eureka.patsnap.com/patent_img/0ddecf1c-7904-4c8e-90a6-e64e68e68c14/US20060270725A1-20061130-C00002.png "N[S(4-aryl-triazol-3-yl)alpha-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors")
![N[S(4-aryl-triazol-3-yl)alpha-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors](https://images-eureka.patsnap.com/patent_img/0ddecf1c-7904-4c8e-90a6-e64e68e68c14/US20060270725A1-20061130-C00003.png "N[S(4-aryl-triazol-3-yl)alpha-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors")
Owner:ARDEA BIOSCI
Non-nucleoside reverse transcriptase inhibitors
Heteroaromatic compounds of Formula I:
are HIV reverse transcriptase inhibitors, wherein R1, R2, R3, R4 and R5 are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
Owner:MERCK CANADA
Non-nucleoside reverse transcriptase inhibitors
InactiveUS20060135556A1Reduce virus spreadSuppression problemBiocideOrganic chemistryNucleoside Reverse Transcriptase InhibitorNon nucleoside inhibitor
Various carbonyl amides are employed in vitro and in vivo as non-nucleoside inhibitors of a reverse transcriptase, and particularly of HIV reverse transcriptase. Therefore, contemplated compounds may be employed in the treatment of HIV infected patients. Further contemplated aspects include pharmaceutical compositions comprising therapeutically effective amounts of contemplated compounds.
Owner:ARDEA BIOSCI
Non-nucleoside reverse transcriptase inhibitors
The present invention relates to a compounds according to formula I, methods for treating diseases mediated by human immunodeficieny virus by administration of a compound according to formula I and pharmaceutical compositions for treating diseases mediated by human immunodeficieny virus containing a compound according to formula I where R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
Owner:ROCHE PALO ALTO LLC
Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof
InactiveUS20050250728A1Good curative effectBiocideCarbohydrate active ingredientsReverse transcriptaseDNA Polymerase Inhibitor
The efficacy of reverse transcriptase and DNA polymerase inhibitors (nucleoside analogs) in a mammalian host is enhanced by administering an effective amount of PNP inhibitor of prodrug of PNP inhibitor and/or an effective amounts of 2′-de-oxyguanosine and/or prodrugs thereof.
Owner:BIOCRYST PHARM INC
Combination therapy comprising the use of protein kinase C modulators and Histone Deacetylase inhibitors for treating HIV-1 latency
InactiveUS20100166806A1Adverse propertyPrevent HIV-1-induced cytotoxicityBiocideOrganic chemistryReverse transcriptaseHydroxamic acid
The invention relates to a combination of treatments, more particularly a combination treatment for HIV-1 infection. The present invention is directed to the use of bryostatin-1 and their natural and synthetic derivatives for AIDS therapy, in particular to the use of bryostatins in combination with other active drugs such as Histone Deacetylases (HDACs) inhibitors and anti-retrovirals, for the treatment of HIV-1 latency. According to the present invention, we provide a combination therapy for the treatment of HIV-1 latency which employs bryostatin-1 (and analogues) and one of the following HDAC inhibitors; valproic acid, butyrate derivatives, hydroxamic acids and benzamides. While HDACi can be used in continuous dosing protocol, bryostatins can be used following a cyclical dosing protocol. Bryostatins can be formulated in pharmaceutical acceptable carriers including nanoparticles, phospholipids nanosomes and/or biodegradable polymer nanospheres. This combination therapy needs to be used in patients treated with antiretroviral therapy (HIV-1 protease inhibitors, HIV-1 reverse transcriptase inhibitors, HIV-1 integrase inhibitors, CCR5 co-receptor inhibitors and fusion inhibitors).
Owner:APHIOS
6- (Heterocyclyl-substituted Benzyl) -4-Oxoquinoline Compound and Use Thereof as HIV Integrase Inhibitor
InactiveUS20080207618A1Strong inhibitory activityEffective anti-HIV agentsBiocideOrganic chemistryAnti-HIV AgentSide effect
The present invention relates to a compound represented by the following formula [I]
wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutical composition, an anti-HIV agent and an HIV integrase inhibitor containing such compound. The compound of the present invention has an HIV integrase inhibitory activity, and is useful as an anti-HIV agent, or as an agent for the prophylaxis or treatment of AIDS. In addition, by the combined use with other anti-HIV agents such as a protease inhibitor, a reverse transcriptase inhibitor and the like, it can be a more effective anti-HIV agent. Because it shows integrase-specific high inhibitory activity, the compound can be a pharmaceutical agent safe on human body, which causes only a fewer side effects.
Owner:JAPAN TOBACCO INC
Combination therapy
ActiveUS8633219B2Low effective doseEffective treatmentBiocideOrganic chemistrySide effectCombined Modality Therapy
The present invention relates to a combination therapy for treating an HIV infection or inhibiting integrase comprising (S)-6-(3-Chloro-2-fluorobenzyl)-1-(1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (“Compound A”) or a pharmaceutically acceptable solvate or salt thereof in combination with at least one other anti-HIV agent. In some embodiments of the present invention, the other anti-HIV agents are chosen from reverse transcriptase inhibitors and protease inhibitors. In certain embodiments of the present invention, the other anti-HIV agents are chosen from AZT, 3TC, PMPA, efavirenz, indinavir, nelfinavir, a combination of AZT / 3TC, and a combination of PMPA / 3TC. Since Compound A has a high inhibitory activity specific for integrases, when used in combinations with other anti-HIV agents it can provide a combination therapy with fewer side effects for humans.
Owner:JAPAN TOBACCO INC
Methods, compositions, formulations, and uses of cellulose and acrylic-based polymers
InactiveUS20050244365A1Easy to chargeLow pKaAntibacterial agentsCosmetic preparationsDisinfectantReverse transcriptase
Compositions, formulations, and methods for the treatment or prevention, or decreasing the frequency of transmission of a virus (such as human immunodeficiency virus type 1 (HIV-1), Herpes Simplex virus type 1 (HSV1), or Herpes Simplex Virus Type 2 (HSV2), or other virus), or a bacterial infection (such as Trichomonas vaginalis, Neisseris gonorrhoeae Haemopholus ducreyl, or Chlamydia trachomatis, or other bacterial species), or a fungal infection, using an anionic cellulose- or acrylic-based oligomer, polymer, or copolymer. The present invention also includes administering a therapeutically effective amount of said oligomer, polymer, or copolymer, or a pharmaceutically acceptable salt thereof, or with a pharmaceutically acceptable carrier or diluent, thereof. The invention relies on the unique biochemical substitution of the cellulose or acrylic backbone such that the resultant molecule can remain molecularly dispersed in solution (or gel or other formulation) and mostly dissociated over a wide range of physiological microenvironments, such as the low pH found within the vaginal lumen, preferably from a pH of 14 to below 3.5. These specific substitutions also impart on the resultant molecule potent antiviral, anti-bacterial, and anti-fungal properties. In addition, these compositions can be used as general disinfectants for human use such as in contact lens solutions, mouthwashes, toothpastes, suppositories, or as more generalized disinfectants found in soaps, household cleaning products, paints, water treatments modalities, or can be incorporated into cosmetic, and can be used as vehicles for drug delivery, an adjuvant in a therapeutic formulation, or as a preservative. These compounds can be delivered in a liquid or solid dosage form and can be incorporated into barrier devices such as condoms, diaphragms, or cervical caps, to help prevent the transmission of STDs. The compounds of this invention can also be used in combination therapies with other classes of antiviral, antibacterial, or antifungal agent having similar or differing mechanisms of action including, but not limited to, anionic or cationic polymers, copolymers, or oligomers, surfactants, protease inhibitors, DNA or RNA polymerase inhibitors (including reverse transcriptase inhibitors), fusion inhibitors, cell wall biosynthesis inhibitors, integrase inhibitors, or virus or bacterial attachment inhibitors.
Owner:NOVAFLUX INC +1
Non-nucleoside reverse transcriptase inhibitors
Disclosed herein are compounds of formula Ar1—X—W—Ar2 wherein Ar1 and Ar2 represent aryl groups characterized generally as aromatic heterocycles (e.g. imidazolyl or tetrazolyl) or carbocycles (e.g. phenyl or naphthalenyl); the aryl groups are optionally substituted or fused with other heterocycles or carbocycles; the aryl groups can bear substituents such as alkyl, halo or O-alkyl. X is a heteroatom, a valence bond or an optionally substituted divalent methylene, and W represents a spacer; typical spacers include divalent alkylene or alkylene-amido, -amido or -oxy radicals, which may optionally be substituted (e.g. hydroxyl or oxo). A typical compound is a derivative of 2-(N-napthalenyltetrazolylthio)-N-(2-nitrophenyl)acetamide. The compounds have inhibitory activity against Wild Type and single or double mutant strains of HIV.
Owner:BOEHRINGER INGELHEIM INT GMBH
Non-nucleoside reverse transcriptase inhibitors
Heteroaromatic compounds of Formula I:are HIV reverse transcriptase inhibitors, wherein R1, R2, R3, R4 and R5 are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
Owner:MERCK CANADA
Indole compound and application thereof as HIV-1 reverse transcriptase inhibitor
InactiveCN103113285AOrganic active ingredientsOrganic chemistryNucleoside Reverse Transcriptase InhibitorStereochemistry
The invention belongs to the field of medical technology, and specifically discloses an indole compound and an application thereof as an HIV-1 reverse transcriptase inhibitor. The indole compound disclosed by the invention has a structural general formula: wherein the formula is described in the specification.
Owner:WUHAN UNIV
Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
The present invention provides compositions and methods for the treatment of HIV infection. In particular, the present invention provides non-nucleoside inhibitors of reverse transcriptase (RT), as well as methods to treat HIV infection using these non-nucleoside inhibitors of RT. In preferred embodiments, the present invention provides a novel class of substituted benzimidazoles, effective in the inhibition of human immunodeficiency virus (HIV) RT.
Owner:US DEPT OF HEALTH & HUMAN SERVICES
Compositions and methods for use of antiviral drugs in the treatment of retroviral diseases resistant to nucleoside reverse transcriptase inhibitors
InactiveUS20050113331A1Inhibiting retroviral replicationReduce viral loadBiocidePhosphorous compound active ingredientsNucleoside Reverse Transcriptase InhibitorDisease
The present invention relates to novel compositions comprising an excision-inhibiting bisphosphonate and a nucleoside reverse transcriptase inhibitor. The present invention also relates to methods for preventing or treating retrovirus-related diseases using a composition comprising a bisphosphonate and a nucleoside reverse transcriptase inhibitor. In a specific embodiment, the invention provides methods for preventing or treating AIDS by administering a bisphosphonate-based compound in combination with 3′-azido-3′-deoxythymidine (AZT) to patients infected with AZT-resistant HIV to improve the effectiveness of AZT therapy.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS +1
Non-nucleoside reverse transcriptase inhibitors
Compounds of formula I, wherein R1, R2, R3, R4, R5, X, Y, and Ar are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and / or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and / or ARC.
Owner:ROCHE PALO ALTO LLC
Hydrophobic Modified Pres-Derived Peptides of Hepatitis B Virus (HBV) and Their Use as Vehicles for the Specific Delivery of Compounds to the Liver
ActiveUS20110027183A1Low immunogenicityShort sequenceOrganic active ingredientsVirusesDiseaseCompound specific
The present invention relates to hydrophobic modified preS-derived peptides of hepatitis B virus (HBV) which are versatile vehicles for the specific delivery of compounds to the liver, preferably to hepatocytes, in vitro as well as in vivo. Any kind of compound, but in particular drugs, such as interferons, viral reverse transcriptase inhibitors or core assembly inhibitors, and/or labels can be specifically targeted to the liver and so be enriched in the liver. This liver targeting can further be used for the targeted diagnosis, prevention and/or treatment of liver diseases or disorders, such as hepatitis, malaria, hepatocellular carcinoma (HCC), as well as for the prevention of HAV, HBV, HCV and/or HDV infection. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified preS-derived peptide(s) and the compound(s) to be specifically delivered to the liver. The present invention furthermore relates to a method for the combined treatment of a liver disease and the prevention of HAV, HBV, HCV and/or HDV infection. The present invention relates also to the use of the preS-derived peptides in gene therapy and the delivery of immunogenic epitopes for hepatocyte-mediated antigen presentation to activate liver-directed immunological responses.
Owner:UNIVERSITY OF HEIDELBERG
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap